According to our results, patients with sarcopenia showed significantly worse inflammatory markers compared to non-sarcopenic ones, supporting the association between sarcopenia, inflammation and worse outcomes in cancer patients treated with anti-PD-1/anti-PD-L1. Here, CD274 is linked to sarcopenia.